Board and committee succession
Board and committee succession Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (“Mediclinic”, the “Company”, or the “Group”) 26 May 2021 Board and committee succession Mediclinic, a leading international private healthcare services group, announces that on 25 May 2021, Messrs Alan Grieve and Trevor Petersen, both independent non-executive directors, informed the Board of their intention to retire as directors of the Company upon the conclusion of their second three-year term of appointment on 14 February 2022. The Board is in the process of actively recruiting two new independent non- executive directors and the Company will make further announcements when it is in a position to confirm the appointments. The Company is mindful that both Messrs Grieve and Petersen were appointed as directors of Mediclinic International Limited (a predecessor company to Mediclinic International plc) on 13 September 2012 and that despite the Board’s views to the contrary, the length of their tenure may, under the UK Corporate Governance Code, be viewed as impairing their independence. In view of this, and in the interests of continuity and significant knowledge of the company, Messrs Grieve and Petersen will continue to serve on the Board in a non-independent capacity from 13 September 2021 until 14 February 2022. In addition, with effect from 13 September 2021: - Dr Felicity Harvey will succeed Mr Grieve as Senior Independent Director of the Company, - Mr Tom Singer will succeed Mr Grieve as Chair of the Audit & Risk Committee, and - Mr Steve Weiner will succeed Mr Petersen as Chair of the Remuneration Committee. Messrs Grieve and Petersen will step down f rom all Board committees with effect f rom 13 September 2021. Mediclinic's Chair, Dame Inga Beale commented: "On behalf of the Board, I would like to thank Alan and Trevor for their commitment and valued contributions to the Board and the Group over many years. We are using the opportunity afforded by their retirements to further refresh and strengthen the Board. I wholeheartedly welcome Felicity’s appointment as Senior Independent Director, Tom’s appointment as Chair of the Audit and Risk Committee and Steve becoming Chair of the Remuneration Committee". This announcement is made in accordance with the requirement of LR 9.6.11. About Mediclinic International plc Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates (“UAE”). The Group’s core purpose is to enhance the quality of life. Its vision is to be the partner of choice that people trust for all their healthcare needs. Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets. At 31 March 2021, Mediclinic comprised 74 hospitals, five sub-acute hospitals, two mental health facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and f our day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five sub -acute hospitals, two mental health facilities and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid -2022. The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE. For further information, please contact: Investor Relations, Mediclinic International plc James Arnold, Head of Investor Relations firstname.lastname@example.org +44 (0)20 3786 8181 Media queries FTI Consulting Ben Atwell/Ciara Martin – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd Date: 26-05-2021 08:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.
More from Mediclinic International plc
Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.